|
GB201607978D0
|
|
Inhibitory compounds
|
|
GB201515351D0
|
|
Antibody
|
|
GB201403538D0
|
|
Pharmacologically active compounds
|
|
GB201306394D0
|
|
Cancer biomarker
|
|
GB201211606D0
|
|
Method for reprogramming somatic cells to pancreatic beta-cells
|
|
GB201009654D0
|
|
Nucleic acid methyltransferase
|
|
GB0818241D0
|
|
Compounds and their use
|
|
GB0816145D0
|
|
a-Galactosylceramide derivatives
|
|
GB0812419D0
|
|
Nucleic acid methyltransferase
|
|
GB0808630D0
|
|
Histone modifying endopeptidase
|
|
GB0802670D0
|
|
Protein methyltransferase
|
|
GB0718560D0
|
|
Compounds and their use
|
|
GB0718561D0
|
|
Compounds and their use
|
|
GB0718562D0
|
|
Compounds and their use
|
|
GB0715600D0
|
|
New therapeutic agents
|
|
GB0610046D0
|
|
Materials and methods relating to the diagnosis and treatment of cancer
|
|
GB0520068D0
|
|
av peptide ligand
|
|
GB0303105D0
|
|
Isoxazole compounds
|
|
GB0224015D0
|
|
DNA repair enzymes
|
